Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
Late-clinical stage T-cell immunotherapy company AlloVir appointed Ugo Perlingieri to the position of general manager of Europe and Middle East operations. Perlingieri comes to AlloVir from Alexion Pharma Italy, where he served as vice president and general manager.
Calliditas Therapeutics announced Richard Philipson will become the company’s chief medical officer. Philipson was most recently chief medical officer of UK biotech company Trizell.
Laura Roca-Alonso, Gyroscope Therapeutics’ previous director of business development, has joined AI drug discovery biotech e-therapeutics as its chief business officer.
Geoff Metcalf has been named vice president of clinical diagnostics of Flagship Biosciences. Previously, Metcalf was head of strategic planning at Siemens Diagnostics.
Marco Londei will now serve as CEO of Gadeta. Before joining Gadeta, Londei was chief development officer and chief medical officer of AnaptysBio.
Myra Rosario Herrle, the most recent senior director of AbbVie’s oncology global regulatory strategy, has been appointed vice president of regulatory affairs at GlycoMimetics.
Harout Semerjian has been named president and CEO of Immunomedics. Semerjian most recently held the position of executive vice president and chief commercial officer at Ipsen.
ImmunoPrecise appointed Yasmina Abdiche to the role of chief scientific officer. Prior to this position, Abdiche was chief scientific officer at Carterra.
Gary Zieziula has been named president of Kyowa Kirin’s North America division. Zieziula’s most recent position was president and managing director of EMD Serono’s North America division.
Locana appointed Micah Mackison to the role of chief business officer. Mackison joins the company from Assembly Biosciences, where he served as senior vice president of corporate development and strategy.
John McKew, chief scientific officer of Lumos Pharma, has been promoted by the company to also serve as chief operating officer.
Neil Tween will now serve as chief financial officer of Owlstone Medical. Tween leaves his previous position as vice president and group financial controller of GW Pharmaceuticals to join Owlstone.
Debra Barker has been appointed by Polyneuron to the role of chief medical officer. Previously, Barker was chief medical and development officer of Polyphor.
Precision NanoSystems announced the hiring of Andrew Geall, who will take on the role of chief scientific officer. Geall was most recently the RNA vaccine platform leader at Novartis Vaccines.
Lisa von Moltke has been named chief medical officer of Seres Therapeutics. Prior to taking this role, von Moltke served as head of clinical development at Alkermes.
Oncology company Vor Biopharma named Robert Pietrusko the company’s new chief regulatory and quality officer. Pietrusko was most recently vice president of global regulatory affairs and quality and executive officer at ViroPharma.
Robert Yu has been appointed president and CEO of Korea-based Yuyu Pharma. Most recently, Yu was Yuyu’s chief operating officer.